INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Narrative review / 2005

Curcumin demonstrates anti-inflammatory and anti-cancer properties with sufficient gastrointestinal bioavailability to support phase II clinical trials.

This review evaluates curcumin, a polyphenol derived from turmeric, regarding its anti-inflammatory and anti-cancer properties following oral or topical delivery. Mechanisms include antioxidant effects, inhibition of signaling pathways, modulation of cellular enzymes, immune modulation, and apoptosis induction. While low systemic bioavailability may limit concentrations in certain tissues, biologically active levels in the gastrointestinal tract have been demonstrated in animals and humans, supporting phase II clinical trials in patients with gastrointestinal lesions.

Study type
Narrative review
Who was studied
Patients with invasive malignancy or pre-invasive gastrointestinal lesions
What was measured
Anti-inflammatory, anti-cancer mechanisms, bioavailability, and clinical evaluation potential of curcumin

THE PAPER

Curcumin: the story so far.

Sharma RA, Gescher AJ, Steward WP. Eur J Cancer, 2005.

PubMed 16081279 ↗DOI 10.1016/j.ejca.2005.05.009 ↗

CancerGut & microbiome

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.